you, Thank And good Mark. everyone. morning,
first quarter there impact reported our today corticosteroid. of In quarter, the X.X% postsurgical, COVID-XX. me decrease Symphony Let INVELTYS of of over XXXX prescriptions by Health, INVELTYS, fourth the with which of to represents a over ocular twice-daily, due XX,XXX were approximately begin the
COVID-XX X% two XX% of ocular time fourth to overall X%, first of during while INVELTYS XXXX down down to period. market same the the months prescriptions compared quarter impacts, market the QX, prior were steroid was the branded Through was up and
as As federal ocular most of procedures, restrictions pandemic continuing includes COVID-XX and the into surgeries. INVELTYS March implemented and have elective quarter, which the governments beginning to, in by affected have local Mark in alluded ongoing second been XXXX on prescriptions
limitations expect negatively the these revenue INVELTYS impact for full year XXXX. to We
are That said, couple encouraged of reasons. we for a
States, the that believe lifted, move procedures eye gives United First, to revenues our prescriptions growth. professionals to which us return are care will INVELTYS' deferred confidence we based and on restrictions once reschedule interactions physicians across will with quickly
report week elective Health, In recent weekly XX% we up fact, from week-over-week since in achieved X.X%, INVELTYS growth market most procedures were early Symphony overall first prescriptions the increases deferral and the marking in the NRxs began March. of of
COVID-XX were of onset the and suggesting positive to quarter-over-quarter, demand. prior growth strong prescriptions tracking up continued pandemic, trends Second,
our to We continue to reception strong target care professional the encouraged among be audience. INVELTYS eye by
strong we new prescription XX.X% of market care a to branded report believe profile effectiveness INVELTYS share reflects XX% strength both among the the the had achieved our called-on INVELTYS having of prior reception and of already of pandemic, eye prescribed and Kala We clinical the sales this the professionals. team.
and in-person over to to our we offices, virtually virtual with we customers team web-based to was technologies. swiftly a clinics telephone to force suspended with continues all last weeks. visits the While have our provide transition support able pleased The their productivity are interactions including physicians and hospitals, sales substantially several working through both and model
for federal, to work to it sales follow Going is forward, for Disease continue continue return to employees to well appropriate all we'll when governments state recommendations local we as force, and the practices. Control as Centers assess normal U.S. from including Prevention, and will and our
calls to for field, approach to those individual Several to to have practices phased a with include surgeries allow states to sales states And sales as already do begun representatives states see representatives in in elective in-person willing will for to business reengage begun those are so. representatives. are the open return re-commence. that and This sales our have
parallel to potential launch the later for execute our on we a commercial In launch on this busy EYSUVIS. been year. well-positioned ongoing preparations we has And with are believe INVELTYS, efforts team with
overlap dry representatives. prescribers, eye to to EYSUVIS, the collectively approves of approval top believe will to XXX significant prescriptions. the dry Kala sales Given expand XXX approximately for relying on and XX FDA plan targets existing after to EYSUVIS, professionals who INVELTYS launch to our the able EYSUVIS sales represent our in be approximately we If target we we force soon eye XX% all
professionals, prescriptions. all sales XX% force allow size of eye effectively us about this are eye for of cover care who the A dry will to responsible
Our quickly Account dry will approved. reviews eye in leverage engage formulary to preparing and is and disease drive we the discussions team payers state to Director of when team EYSUVIS if
are a EYSUVIS commercial eye managed disease have diagnosed We eye that million there XX believe million of tremendous been represents XX that approximately from and opportunity. suffering an care by We which U.S., over are in estimate dry people professional. the
they are and these therapies. Our XX% rather are variety approximately adequately of research flares by quantitative to doctors managed experience feedback continuous dry These patients both suggests market symptoms. inflammatory-driven a triggers XX% suggest, flares, that eye patients from and responses to than of current not episodic
of believe therapies prescription and XX% patients shared on artificial XX% daily suffer flares. breakthrough we that chronic As from we previously, patients tears approximately on approximately of
Moreover, demonstrated And a by provided there's prescription options treated this their treatment among research high discontinuation significant side-effect patients options. with insufficient our efficacy rate eye due existing profiles. is these dry to data indicates and
new that symptoms by relief provide signs inflammation clear rapid disease, of of a is There effective the the well-tolerated address treatment need patients. of for is eye and and option dry a can underlying the
three care eye times there We their diagnosed the expect disease professional supported XX to dry more that already the by uptake launch year. a average visiting than are two at on fact of eye to EYSUVIS be million patients
Approximately That these drive we new occur treatment They the already dry XX% patient to means doctor's the looking of explicitly often don't flare. offices. office because is a actively into there, visits option. for need eye experiencing a patients are
the EYSUVIS to prescription only If symptoms well-positioned eye an and of short-term first-line to signs is the EYSUVIS for be eye approved, for which dry disease. believe have treatment steroid and flares. indication dry will disease, includes We the the become ocular preferred of first therapy
for Our to that reasons. research a important is care few professionals demonstrates eye it
very of efficacy data clinical the favorably is vary by First, and or prescribers. viewed EYSUVIS' safety steroids
associated inherent risk prescribing with steroids. Second, off-label
having by dry been safety the FDA. comfortable Third, more patients are that eye of vetted the efficacy their indication labeling and has fourth, a and medicine in
availability eye interested steroid in would a eye and indication the EYSUVIS doctors for most prescribe FDA-approved of they in stated that indicated, specifically their of patients. an XX% with dry majority surveyed dry market they of research are a the
that market eye potentially eye EYSUVIS. dry apply market, the patients to prescribed more could million be physician there X are than dry estimate disease feedback we from that research disease When we
estimate a capitalize we are per dry of excess total that potential the year U.S. annually. market billion Additionally, in alone, days $X addressable in eye XXX approved, over flare there If million representing available it’s We be short-term and well-positioned believe opportunity. will rapid of of dry only we this the treatment signs to action the symptoms onset to treat a on eye with disease.
Mary the to discuss financial I our over to will now call turn results.
